Get the Stockscreener App
0.98
2.42%
0.0232
After Hours:
.94
-0.04
-4.08%
Ocean Biomedical Inc stock is traded at $0.98, with a volume of 18,743.
It is up +2.42% in the last 24 hours and down -13.27% over the past month.
Ocean Biomedical Inc is a biopharmaceutical company. It is dedicated towards partnering with inventor-scientists and research institutes to bridge the gap between basic research and clinical development, to get new medicines to the patients who need it most.
See More
Previous Close:
$0.9568
Open:
$0.97
24h Volume:
18,743
Relative Volume:
0.22
Market Cap:
$32.23M
Revenue:
-
Net Income/Loss:
$-77.50M
P/E Ratio:
-0.2553
EPS:
-3.839
Net Cash Flow:
$-8.35M
1W Performance:
+8.89%
1M Performance:
-13.27%
6M Performance:
-74.11%
1Y Performance:
-74.87%
1-Day Range:
$0.9301
$0.99
1-Week Range:
$0.7539
$1.09
52-Week Range:
$0.52
$7.79
Ocean Biomedical Inc Stock (OCEA) Company Profile
Name
Ocean Biomedical Inc
Sector
Industry
Phone
(646) 908-2658
Address
515 MADISON AVE SUITE 8078, NEW YORK
Ocean Biomedical Inc Stock (OCEA) Latest News
Ocean Biomedical, Inc. (NASDAQ:OCEAW) Short Interest Update - Defense World
Fralin Biomedical Institute Award Supports Innovation in Brain Cancer Treatment - The Roanoke Star
IPO News: Everything you need to know about BioAge Labs’ IPO - AlphaStreet
Biotech Stocks Are Tumbling — But The Top 5 Are Standouts - Investor's Business Daily
OceanFirst Financial (NASDAQ:OCFC) Hits New 52-Week High at $18.97 - MarketBeat
Delisting of Securities of OceanTech Acquisitions I Corp.; OCA Acquisition Corp.; Assure Holdings Corp.; Selina Hospitality PLC; Maquia Capital Acquisition Corporation; ToughBuilt Industries, Inc.; SunPower Corporation; Meta Materials Inc.; Talis Biomedical - StockTitan
What's Going On With Odyssey Marine Exploration Stock? - Benzinga
OM Investors Have Opportunity to Lead Outset Medical, Inc. Securities Fraud Lawsuit with the Schall Law Firm - Stockhouse Publishing
OM CLASS ACTION: Outset Medical, Inc. Stockholders Should - GlobeNewswire
OM CLASS ACTION: Outset Medical, Inc. Stockholders Should Contact Robbins LLP for Information - The Bakersfield Californian
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Outset Medical, Inc.OM - PR Newswire
Guardian Pharmacy seeks to raise up to $108 mil in US IPO - AlphaStreet
Gaining Ground: Outset Medical Inc (OM) Closes Lower at 0.52, Down -1.34 - The Dwinnex
Ocean Power Technologies Stock Climbs On Q1 Results: Details - Benzinga
Oceaneering International, Inc. [OII] stock was sold by Beachy Karen H at the price of US$75702.0 - Knox Daily
Outset Medical (OM) Shares Down 94% Since Disclosing FDA Warning Letter, Class Action Pending – Hagens Berman - ForexTV.com
Lawsuit Notice: Investors who lost money with shares of Outset - openPR
Idiopathic Pulmonary Fibrosis Treatment Drug Market to Increase 2 Folds by 2034 | DelveInsight - The Malaysian Reserve
Dr. Chirinjeev Kathuria - Smart Business Dealmakers
Everything you need to know about Zenas BioPharma’s IPO - AlphaStreet
Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Patent Issued for PfGARP Malaria Antibodies Central to Company’s Malaria Treatment and Prevention Platforms - ForexTV.com
Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Patent - GlobeNewswire
Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Patent Issued for PfGARP Malaria Antibodies Central to Company’s Malaria Treatment and Prevention Platforms - Morningstar
Ocean Biomedical, Inc. Announces Receipt of Notice from - GlobeNewswire
Ocean Biomedical Faces Nasdaq Compliance Challenges - TipRanks
Ocean Biomedical, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q - StockTitan
Ocean Biomedical (NASDAQ: OCEA) Research Summary - AlphaStreet
Ocean Biomedical Inc. (OCEA) Stock: Navigating a Year of Volatility - The InvestChronicle
U.S. shares mixed at close of trade; Dow Jones Industrial Average up 0.16% - MSN
Ocean Biomedical secures additional financing, issues equity - Investing.com
Financial Health Check: Examining Ocean Biomedical Inc. (OCEA)'s Key Ratios – DWinneX - The Dwinnex
Ocean Biomedical Inc. (OCEA) is a good investment, but the stock may be overvalued – US Post News - US Post News
Everything you need to know about OS Therapies’ upcoming IPO - AlphaStreet
3-Month SOFR (SQZ24) Quote - The Globe and Mail
Alumis looks to raise $300 million in IPO. Here’s what you need to know - AlphaStreet
Idiopathic Pulmonary Fibrosis Pipeline Analysis 2024: FDA Approval, Clinical Trials, Therapies, MOA, ROA by - EIN News
The Role of Horseshoe Crabs in the Biomedical Industry and Recent Trends Impacting Species Sustainability - Frontiers
Investing in Ocean Biomedical Inc. (OCEA) might be an excellent idea, but the stock is currently overvalued ... - US Post News
Best Penny Stocks for Today (Charts Updated Daily) • Benzinga - Benzinga
Biotech Stock Roundup: ZGNX's Acquisition News, REGN, BLUE's Updates & More - Yahoo Lifestyle UK
Biotech Stocks: The Top 5 To Watch As Shares Broadly Struggle - Investor's Business Daily
Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday - InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday - InvestorPlace
TSX 60 Index (TXSX) QuotePress Release - The Globe and Mail
Stocks Fall Before CPI Report and FOMC Meeting - The Globe and Mail
Stocks Settle Higher Ahead of the Tue/Wed FOMC Meeting - The Globe and Mail
Ocean Biomedical congratulates joint venture partner Virion TherapeuticsTipRanks.com - TipRanks
Tempus AI gears up for IPO. Here’s everything you need to know - AlphaStreet
Ocean Biomedical (NASDAQ: OCEA) Congratulates Joint Venture Partner, Virion Therapeutics, on Positive ... - GlobeNewswire
Ocean Biomedical (NASDAQ: OCEA) Congratulates Joint Venture Partner, Virion Therapeutics, on Positive Immunogenicity Results from Their Lead Checkpoint Modifier-Containing Immunotherapy, VRON-0200, for HBV Functional Cure, at EASL 2024 - ForexTV.com
Ocean Biomedical (NASDAQ: OCEA) Congratulates Joint Venture Partner, Virion Therapeutics, on Positive Immunogenicity Results from Their Lead Checkpoint Modifier-Containing Immunotherapy, VRON-0200, for HBV Functional Cure, at EASL 2024 - GlobeNewswire Inc.
Ocean Biomedical Inc Stock (OCEA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):